Inhibition of chemiluminescence by carvedilol in the cell‐free system, whole human blood and blood cells

References

• Savitz SI, Erhardt JA, Anthony JV, Guypta G, Li X, Barone FC, Rosenbaum DM. The novel I3-blocker, carvedilol provides neuroprotection in transient focal stroke. J Cereb Blood Flow Metab 2000;8: 1197–204.
   Google Scholar
• Feuerstein GZ, Bril A, Ruffolo RR Jr. Protective effect of carvedilol in the myocardium. Cardiology 1977;80:41–55.
   Google Scholar
• Ruffolo RR Jr, Feuerstein GZ. Pharmacology of carvedilol. Rationale for use in hypertension, coronary heart disease and congestive heart failure. Cardiovasc Drugs Ther 1997;11:247–56.
   Google Scholar
• Cheng J, Kamiya K, Kodama I. Carvedilol: molecular and cellular basis for its multifaced therapeutic potential. Cardiovasc Drug Rev 2001;2:152–71.
   Google Scholar
• Yue T-L, Wang X, Gue JL, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther 1995;273:1442–9.
   Google Scholar
• Feuerstein G, Liu G-L, Yue T-L, Cheng H-Y, Hieble JP, Arch JRS, Ruffolo RR Jr, Ma X-L. Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. Eur J Pharmacol 1998;351:341–50.
   Google Scholar
• Dandona P, Karne R, Ghanim H, Hamouda W, Aljada A, Magsino C Jr. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000;101:122–4.
   Google Scholar
• Petriková M, Jan'ainová V, Nosár R, Májeková M, Danihelová E. Antiplatelet activity of carvedilol in comparison to propranolol. Platelets 2002;13:479–85.
   Google Scholar
• Nosál' R, Jadéinová V. Cationic amphiphilic drugs and platelet phospholipase A2 (cPLA2). Thromb Res 2002;105:339–45.
   PubMed Web of Science ®Google Scholar
• Drábiková K, Nosál' R, Jananová V,M, Lojek A. Reactive oxygen metabolite production is inhibited byhistaminev and HI-antagonist Dithiaden® in human PMN leukocytes. Free Rad Res 2002;36:975–80.
   Google Scholar
• Lojek A, Cil M, Slaviková H, Ddková M, Vondrgek J, Kubala L, Ricz I, Hamar J. Leukocyte mobilization, chemiluminescence response and antioxidative capacity of the blood in intestinal ischemia and reperfusion. Free Rad Res 1997;27:359–67.
   Google Scholar
• Jananová V, Drábiková K, Nosál' R, Petriková M, Ci M, Lojek A. Danihelová E. Inhibition of FMLP-stimulated neutrophil chemiluminescence by blood platelets increased in the presence of the serotonin-liberating drug chloroquine. Thromb Res 2003;109:293–8.
   Google Scholar
• Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase and bacterial killing. Blood 1998;92:3007–17.
   Google Scholar
• Furtmiiller PG, Obinger C, Hsuanyu Y, Dunford HB. Mechanism of reaction of myeloperoxidase with hydrogen peroxide and chloride ion. Eur J Biochem 2000;267:5858–64.
   PubMedGoogle Scholar
• Arnholdt J, Furtmilller PG, Regelsberger G, Obinger C. Redox properties of the couple compound I/native enzyme of myeloperoxidase and eosinophil peroxidase. Eur J Biochem 2001;268:5142–8.
   PubMedGoogle Scholar
• Nakamura M, Nakamura S. One- and two-electron oxidations of luminol by peroxidase systems. Free Rad Biol Med 1998;24:537–44.
   PubMed Web of Science ®Google Scholar
• Gao F, Chen J, Lopez BL, Christopher TA, Gu J, Lysko P, Ruffolo RR Jr, Ohlstein EH, Ma XL, Yue TL. Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol 1998;351:341–50.
   PubMed Web of Science ®Google Scholar
• Wittmann S, Frolich D, Daniels S. Characterization of the human fiVILP receptor in neutrophils and in Xenopus oocytes. Br J Pharmacol 2002;135:1375–82.
   Google Scholar
• Takahashi R, Edashige K, Sato EF, Inoue M, Matsuno T, Utsumi K. Luminol chemiluminescence and active oxygen generation by activated neutrophils. Arch Biochem Biophys 1991;285:325–30.
   PubMed Web of Science ®Google Scholar
• Weisdorf DJ, Thayer MS. Occult intracellular calcium pools: relevance to neutrophil oxidant production. J Lab Clin Med 1989;114:260–5.
   PubMed Web of Science ®Google Scholar
• Smith R, Justen JM, Sam LM. Function and stimulus-specific effects of phorbol 12-myristate 13-acetate on human polymorphonuclear neutrophils: autoregulatory role for protein kinase C in signal transduction. Inflammation 1988;12: 597–611.
   Google Scholar
• Jan6inová V, Nosál' R, Drábiková K, Danihelová E. Cooperation of chloroquine and blood platelets in inhibition of polymorphonuclear leukocyte chemiluminescence. Biochem Pharmacol 2001;62:1629–36.
   Google Scholar
• Feuerstein G, Schusterman NH, Rufollo RR Jr. Carvedilol update IV: Prevention of oxidative stress, cardiac remodeling and progression of congestive heart failure. Drugs Today 1997;33:453–73.
   Google Scholar
• Varin F, Cubeddu LX, Powel JR Liquid chromatographic assay and disposition of carvedilol in healthy volunteers. J Pharm Sci 1986;75:1195–7.
   PubMed Web of Science ®Google Scholar
• Yue TL, McKenna J, Gu JL, Cheng HY, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new vasodilating 13-adrenoceptor blocking antihypertensive drug protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils. Cardiovasc Res 1994;28:400–6.
   PubMed Web of Science ®Google Scholar
• Habon T, Szabados E, Kesmarky G, Halmosi R, Pat T, Sumegi B, Toth K. The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals. Cardiovasc Res 2001;52:153–60.
   Google Scholar
• Ross D, van Bruggen R, Meischl C. Oxidative killing of microbes by neutrophils. Microb Infect 2003;5:1307–15.
   PubMed Web of Science ®Google Scholar
• Asbrink S, Zickert A, Bran J, Gyllenhammar H, Palmblad J. No effect of carvedilol on nitric oxide generation in phagocytes but modulation of production of superoxide ions. Biochem Pharmacol 2000;59:1007–13.
   Google Scholar
• Dana TL, Leto HL, Malech R, Levy R. Essential requirement of cytosolic phospholipase A2 for activation of the phagocyte NADPH oxidase. J Biol Chem 1998;273:441–5.
   PubMed Web of Science ®Google Scholar
• Nosál' R, Drábiková K, Jan'éinová V, Ci M, Lojek A. Histamine, dithiaden and human polymorphonuclear leukocytes in vitro. Inflamm Res 2003;52:519–20.
   Google Scholar